Autoimmune disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:36 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Autoimmune disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Using PET Imaging to See How [89Zr]Zr-DFO-CIT-013 Spreads in Patients with Inflammatory Mediated Immune Diseases https://clinicaltrials.eu/trial/study-using-pet-imaging-to-see-how-89zrzr-dfo-cit-013-spreads-in-patients-with-inflammatory-mediated-immune-diseases/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/study-using-pet-imaging-to-see-how-89zrzr-dfo-cit-013-spreads-in-patients-with-inflammatory-mediated-immune-diseases/ This study involves patients with inflammatory mediated immune diseases, which are conditions where the body’s immune system causes long-lasting inflammation that can damage tissues and organs. The study will specifically include people with rheumatoid arthritis, a disease that causes painful swelling in the joints, and hidradenitis suppurativa, a skin condition that causes painful lumps and tunnels under the skin. The treatment being studied is [89Zr]Zr-DFO-CIT-013, which is a radioactive substance that can be seen on special imaging scans. This substance is given as an infusion into a vein.

The purpose of this study is to see where the radiolabeled substance travels and collects in the body of patients with these inflammatory immune diseases. During the study, participants will receive a single dose of [89Zr]Zr-DFO-CIT-013 through an intravenous injection, which means it will be given directly into a vein. After receiving the treatment, participants will undergo PET-CT imaging scans, which are special types of scans that combine two imaging methods to create detailed pictures of the inside of the body. The main scan will be done 24 hours after the treatment is given.

The study will also monitor participants for any unwanted effects that may occur after receiving the treatment and will measure the levels of the substance in the blood over time. The imaging scans will show how much of the radioactive substance collects in different organs and body systems, and doctors will compare these patterns between patients with different types of inflammatory immune diseases. The maximum amount of the treatment that can be given is 20 milligrams, and the treatment period lasts for one day.

]]> Study on Anti-CD19 CAR T-Cell Therapy for Patients with Refractory Systemic Autoimmune Diseases Using Levetiracetam, Fludarabine, and a Drug Combination https://clinicaltrials.eu/trial/study-on-anti-cd19-car-t-cell-therapy-for-patients-with-refractory-systemic-autoimmune-diseases-using-levetiracetam-fludarabine-and-a-drug-combination/ Wed, 29 Apr 2026 15:00:27 +0000 https://clinicaltrials.eu/trial/study-on-anti-cd19-car-t-cell-therapy-for-patients-with-refractory-systemic-autoimmune-diseases-using-levetiracetam-fludarabine-and-a-drug-combination/ This clinical trial is focused on studying the effects of a treatment called anti-CD19 CAR T-cell therapy in people with certain types of autoimmune diseases that are difficult to treat. These diseases include Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Dermatomyositis/Polymyositis (DM/PM), and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV). The treatment involves using a patient’s own immune cells, which are modified in a laboratory to better target and fight the disease.

The purpose of the study is to evaluate the safety and initial effectiveness of this therapy in patients with active forms of these diseases. Participants will receive the treatment through an intravenous infusion, which means it is delivered directly into the bloodstream. The study will monitor participants for any side effects and changes in their condition over a period of time. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects of the therapy.

Throughout the study, researchers will keep track of how the treatment affects the immune system and the levels of certain antibodies in the blood. The study aims to provide valuable information on whether this therapy can be a safe and effective option for people with these challenging autoimmune diseases. The trial is expected to continue until early 2026, with recruitment starting in 2024.

]]> Study on Stopping Prednisone for Patients with Inflammatory or Autoimmune Disorders https://clinicaltrials.eu/trial/study-on-stopping-prednisone-for-patients-with-inflammatory-or-autoimmune-disorders/ Wed, 29 Apr 2026 14:57:37 +0000 https://clinicaltrials.eu/trial/study-on-stopping-prednisone-for-patients-with-inflammatory-or-autoimmune-disorders/ This clinical trial is focused on studying the effects of stopping or gradually reducing the use of glucocorticoids, a type of steroid medication, in patients with inflammatory or autoimmune disorders. These disorders occur when the body’s immune system mistakenly attacks its own tissues, causing inflammation and other symptoms. The medication being studied is Prednisone, which is commonly used to reduce inflammation and suppress the immune system. The trial will compare two approaches: stopping the medication immediately or gradually reducing the dose over four weeks.

The purpose of the study is to determine if stopping glucocorticoid treatment quickly is as safe and effective as slowly reducing the dose. Participants will be randomly assigned to one of the two groups. Some participants will receive a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of up to 28 days, during which participants will be monitored for any health changes, including the need for additional treatment or any serious health events.

Throughout the study, participants’ overall health and any symptoms they experience will be closely observed. This includes monitoring for signs of adrenal insufficiency, a condition where the body does not produce enough of certain hormones after stopping steroid treatment. The study aims to provide valuable information on the best way to discontinue glucocorticoid therapy in patients with inflammatory conditions, ensuring their safety and well-being.

]]>